Nasdaq:US$30.22 (+0.49) | HKEX:HK$49.00 (+0.10) | AIM:£4.61 (+0.03)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.